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The central concept in this new system is that a hospital will be allowed to keep the difference if its costs are less than the reimbursement calculated for the diagnosis related groupbut it will have to absorb any excess costs. The belief is that hospitals will be forced to improve the efficiency and cost effectiveness of their services. Radiology departments, for example, which were previously revenue generating areas will now become closely scrutinised cost centres. Attempts will be made to limit the excessive use of laboratory tests, and laboratories should become much more cost efficient. The emphasis in laboratory testing will be on producing a diagnosis rather than a test result. The clinical pathologist should have a key role in developing new attitudes and approaches. Hospitals will also seek sources of revenue outside direct patient care. They will attempt to pool their resources with other health care delivery systems to improve their productivity and cost efficiency. The mix of different diagnoses in patients will be critical, since reimbursement on diagnosis related groups varies with discharge diagnosis. Administrators and hospital staffs will have to work closely together to meet these challenges. The hospitals will closely monitor the type of patient admitted, the length of stay, and the performance of each member of the attending staff.
Preadmission laboratory testing is likely to be used more widely, for it is not reimbursed under diagnosis related groups, and the patient's stay in hospital will not be prolonged by waiting for laboratory results. Testing after discharge is also likely to increase for the same reasons. Laboratories will be forced to operate 24 hours a day, seven days a week to accommodate shorter hospital stays.
There will be more competitive bidding for services throughout the health care system in order to cut costs. This may lead to a decline in the quality of care, becausc fewer skilled workers will be hired, costly quality control activities will be curtailed, continuing medical education will be limited, and test development will become too costly.
Americans have become increasingly aware of the cost of medicine in the past decade. In the next few years they are likely to have greater flexibility in choosing methods for paying for this care. They will continue to demand high quality but affordable medicine.
CURTIS L BAKKEN The partial pressure of oxygen in the arterial and venous blood may be raised substantially by breathing pure oxygen above normal atmospheric pressure. Such hyperoxygenation may be achieved with the help of hyperbaric oxygen pressure chambers, of which there are two types. In monoplace chambers a single patient can be bathed in pure oxygen but is removed from the direct attention of medical personnel, which might have serious implications if the patient developed complications, such as a convulsion. Another disadvantage is that some patients develop severe claustrophobia.' Several patients may be treated in walk in multiplace chambers, and they may be accompanied by trained attendants. In such chambers oxygen is delivered with the help of facemasksbut these often leak in the sealing area around the face and thus allow the ambient air used to compress the chamber to enter. The concentration of oxygen administered may therefore vary between 60% and 100%.2 3 Hyperbaric oxygen is established as a treatment for decompression sickness; it has also been used for patients with carbon monoxide poisoning, osteomyelitis, and gangrene and after a spinal cord injury, but in none of these has it gained general acceptance.1 4 Experimental studies Studies in animals and man have shown that the beneficial effect of hyperbaric oxygen is limited to a relatively narrow range of pressures.5 Pressures higher than 2-5 atm have been found to be toxic, especially to the central nervous system and the respiratory system. Prolonged exposure (six hours or more) ofanimals to pressures of 2-5 atm and above causes perivascular oedema within the brain,6 central necrosis of the spinal cord,7 8 and respiratory failure due to acute pneumonia.9 In the human brain glucose metabolism is found to be optimal at 2-0 atm but is significantly impaired at 2-5 atm.10
At the end of hyperbaric treatment sessions decompression has to be carried out slowly to prevent damage to the central nervous system by gas embolism. Side effects of treatment with hyperbaric oxygen at 2-0 atm are discomfort in the ears (especially during the compression phase), transient reversal of refractive error, and irritation of the respiratory tract."1
In susceptible people-for example, patients with organic lesions of the central nervous system-hyperoxygenation may precipitate epileptic seizures. In healthy subjects hyperbaric oxygen at 3 0 atm and above has considerable adverse effects on functions of the central nervous system and causes visual and acoustic symptoms, vertigo, autonomic nerve dysfunction, muscle twitching, and convulsions; mood changes may range from depression to euphoria.12 13 These adverse effects show great variability not only among subjects but also within subjects from day to day, and convulsions have been observed even after exposure to hyperbaric oxygen at only 2 0 atm.12 13 Brain damage due to multiple sclerosis may lower the threshold for induction of seizures, and indeed epileptic seizures have been observed in 1-5-2-40/ of patients with multiple sclerosis.'4 Seizures may be expected, therefore, as a possible side effect of treatment with hyperbaric oxygen of patients with multiple sclerosis. Recently a case has come to our attention where a patient with multiple sclerosis, without a clear history of epilepsy, had a seizure while receiving treatment with hyperbaric oxygen (C H Hawkes, personal communication). In the electroencephalogram obtained after the event abnormalities were found within the left temporal region indicative of an epileptogenic focus. Hence it would appear imperative that an electroencephalogram should be recorded before treatment with hyperbaric oxygen. Moreover, the potential dangers of administration of hyperbaric oxygen at higher pressures, of fast decompression rates, and the side effects which may occur during treatment with pressures below 2-5 atm all point to the need for treatment with hyperbaric oxygen to be carried out by specially trained medical and nursing staff.
Hyperbaric oxygen in multiple sclerosis
The idea that a vascular component may 31 MARCH 1984 therapeutic studies on animals with experimental allergic encephalomyelitis.
The results of the first study of treatment with hyperbaric oxygen in guinea pigs with experimental allergic encephalomyelitis were inconclusive owing to flaws in its design.32 In a later, better designed and controlled study Warren and coworkers found complete suppression of experimental allergic encephalomyelitis in guinea pigs treated for 34 days.9 Treatment with hyperbaric oxygen was given daily, with 99% oxygen at 2-0 atm for six hours and was effective when started one to six days after sensitisation. Animals in the control groups were treated with normobaric oxygen or compressed air at 2-0 atm. The suppression of the disease in the animals treated with hyperbaric oxygen was only transient: seven to 10 days after discontinuation of the treatment typical clinical signs of experimental allergic encephalomyelitis appeared, and the lesions in the central nervous systems of these animals were indistinguishable from those detected in the controls. When treatment with hyperbaric oxygen was started after the appearance of the first signs of disease-that is, on day 10 after sensitisation-the median survival time was prolonged beyond that of control animals, but the treatment did not suppress the overall progression of the disease. In rats treatment with hyperbaric oxygen was less effective, the development of experimental allergic encephalomyelitis being observed during the treatment period. The mortality, however, was lower than in the control rats.
Oxygen poisoning was observed in guinea pigs but not in rats treated with hyperbaric oxygen.9 It did not occur with intermittent treatment with hyperbaric oxygen (given every other day), but this regimen did not completely suppress the disease-though it still produced a substantial amelioration of experimental allergic encephalomyelitis.
Clinical trials in multiple sclerosis
The clinical course of multiple sclerosis is erratic and unpredictable. Some of the symptoms are subjective, and often the correlation is poor-especially in the earlier stages of the disease-between the clinical activity of multiple sclerosis and the extent and localisation of the characteristic lesions within the central nervous system. Methods are just beginning to be developed for direct monitoring of the disease process by detecting the extent and spread of lesions, and progression of the disease is still judged primarily with the help of clinical diagnostic methods and established scoring systems for function and disability.33 These factors, together with the unpredictability of the clinical course of multiple sclerosis, are grounds for great caution in interpreting results of uncontrolled therapeutic trials, in which the rate of relapses and disease progression during or after the treatment under investigation is compared with that before the treatment. 33 Reliable, objective results can be obtained only when trials are carried out under strictly controlled conditions. 33 All but one of the trials of treatment with hyperbaric oxygen in multiple sclerosis have been carried out in an uncontrolled fashion,34-37 and, in some instances, by therapists not trained in neurology. They can at best be regarded as preliminary trials, establishing the dosage of hyperbaric oxygen and studying the possible toxicity of the treatment. Claims by the authors of these trials for a beneficial effect of treatment with hyperbaric oxygen in multiple sclerosis have to be regarded as unsubstantiated.
Only one small, randomised, placebo controlled trial of 959 hyperbaric oxygen, including 40 patients with clinically definite multiple sclerosis, has been reported so far.1' The treatment was carried out in a multiplace hyperbaric oxygen chamber, with pure oxygen administered using facemasks. The pressure was 2-0 atm, and the daily treatment sessions lasted for 90 minutes; a total of 20 exposures were given over four weeks. The patients in the placebo treated group received a mixture of 10% oxygen and 90°/% nitrogen, also at a pressure of 2-0 atm.
Mild improvement of a transient nature was seen: improvement in functions of the central nervous system such as mobility, coordination, and bladder control and reduction in fatigability resulted in some of the patients treated with hyperbaric oxygen, in changes of two or more points on the Kurtzke brain damage as a result of multiple sclerosis should deter clinicians from recommending their patients for uncontrolled trials or for treatment by non-medically qualified personnel.
